Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).

Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...

Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' rating.

Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ETCompany ParticipantsJay Bradner - Executive ...

MariTide will need to demonstrate a competitive profile against established and emerging treatments to justify Amgen's valuation. Uplizna, while showing promise in generalized myasthenia gravis ...

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

MariTide will need to demonstrate a competitive profile against established and emerging treatments to justify Amgen’s valuation. Uplizna, while showing promise in generalized myasthenia gravis (gMG), ...